Dupixen-话题@MedSci

#Dupixen#

23篇内容 | 1327人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1784850, encodeId=9f401e8485034, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲/再生元的Dupixent在第二次慢性自发性荨麻疹研究中表现欠佳, objectType=article, longId=299150, objectId=53072991502c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53072991502c, replyNumber=0, likeNumber=89, createdTime=2022-06-06, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53072991502c, moduleTitle=赛诺菲/再生元的Dupixent在第二次慢性自发性荨麻疹研究中表现欠佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53072991502c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784849, encodeId=70a51e8484943, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者, objectType=article, longId=295015, objectId=7fac295015e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fac295015e8, replyNumber=0, likeNumber=78, createdTime=2022-12-22, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fac295015e8, moduleTitle=幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fac295015e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784847, encodeId=040c1e84847ed, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=哮喘新药：再生元的Dupixent能够迅速改善儿童的肺功能, objectType=article, longId=211563, objectId=72e22115636f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72e22115636f, replyNumber=0, likeNumber=85, createdTime=2022-03-18, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72e22115636f, moduleTitle=哮喘新药：再生元的Dupixent能够迅速改善儿童的肺功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72e22115636f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784848, encodeId=572b1e84848ae, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲、再生元的Dupixent在慢性自发性荨麻疹中取得积极成果, objectType=article, longId=215175, objectId=1f472151e583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f472151e583, replyNumber=0, likeNumber=89, createdTime=2021-10-27, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f472151e583, moduleTitle=赛诺菲、再生元的Dupixent在慢性自发性荨麻疹中取得积极成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f472151e583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784845, encodeId=a0031e8484531, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲的IL-4/IL-13单抗Dupixent显著减轻儿童的严重哮喘发作, objectType=article, longId=202084, objectId=58c820208475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58c820208475, replyNumber=0, likeNumber=100, createdTime=2021-06-19, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58c820208475, moduleTitle=赛诺菲的IL-4/IL-13单抗Dupixent显著减轻儿童的严重哮喘发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58c820208475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784841, encodeId=68431e84841ca, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=中国NMPA批准Dupixent用于特应性皮炎, objectType=article, longId=196202, objectId=107519620296, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=107519620296, replyNumber=0, likeNumber=134, createdTime=2020-09-26, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=107519620296, moduleTitle=中国NMPA批准Dupixent用于特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=107519620296)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784840, encodeId=558d1e84840c9, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲的IL-4/IL-13单抗Dupixent，在特应性皮炎儿童患者中显示出明显益处, objectType=article, longId=191379, objectId=18d21913e93a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18d21913e93a, replyNumber=0, likeNumber=108, createdTime=2020-04-29, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18d21913e93a, moduleTitle=赛诺菲的IL-4/IL-13单抗Dupixent，在特应性皮炎儿童患者中显示出明显益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18d21913e93a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784846, encodeId=4c2d1e848460a, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=Dupixent在欧盟获得批准用于儿童特应性皮炎, objectType=article, longId=203948, objectId=a74e203948f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a74e203948f7, replyNumber=0, likeNumber=93, createdTime=2021-10-15, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a74e203948f7, moduleTitle=Dupixent在欧盟获得批准用于儿童特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a74e203948f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784844, encodeId=454a1e8484415, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲/再生元Dupixent获FDA突破性疗法认定, objectType=article, longId=200724, objectId=71cb200e24ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71cb200e24ec, replyNumber=0, likeNumber=91, createdTime=2020-11-15, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71cb200e24ec, moduleTitle=赛诺菲/再生元Dupixent获FDA突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71cb200e24ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784843, encodeId=26211e8484313, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, objectType=article, longId=197603, objectId=36c019e60339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36c019e60339, replyNumber=0, likeNumber=88, createdTime=2021-06-14, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36c019e60339, moduleTitle=IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36c019e60339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784842, encodeId=a4651e8484207, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, objectType=article, longId=196203, objectId=838b196203df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=838b196203df, replyNumber=0, likeNumber=105, createdTime=2021-02-05, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=838b196203df, moduleTitle=慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=838b196203df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784838, encodeId=621b1e848383b, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会, objectType=article, longId=182540, objectId=b84d182540dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b84d182540dd, replyNumber=0, likeNumber=86, createdTime=2020-04-06, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b84d182540dd, moduleTitle=全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b84d182540dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784836, encodeId=fdba1e84836de, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉, objectType=article, longId=182189, objectId=dd431821896a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dd431821896a, replyNumber=0, likeNumber=89, createdTime=2019-12-15, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dd431821896a, moduleTitle=欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dd431821896a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784839, encodeId=1b041e84839bb, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会, objectType=article, longId=182567, objectId=ec7418256ef8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec7418256ef8, replyNumber=0, likeNumber=100, createdTime=2020-08-10, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec7418256ef8, moduleTitle=全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec7418256ef8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784835, encodeId=39811e8483552, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, objectType=article, longId=177128, objectId=d21f1e7128a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d21f1e7128a2, replyNumber=0, likeNumber=113, createdTime=2020-07-13, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d21f1e7128a2, moduleTitle=赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d21f1e7128a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784830, encodeId=9d051e84830d4, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=Dupixent中国内地首针注射在博鳌超级医院完成, objectType=article, longId=160831, objectId=754716083134, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=754716083134, replyNumber=0, likeNumber=86, createdTime=2019-11-10, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=754716083134, moduleTitle=Dupixent中国内地首针注射在博鳌超级医院完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=754716083134)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784831, encodeId=42c91e8483142, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , objectType=article, longId=161247, objectId=7cfc16124ea4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cfc16124ea4, replyNumber=0, likeNumber=73, createdTime=2019-09-04, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cfc16124ea4, moduleTitle=赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cfc16124ea4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784837, encodeId=98111e84837bd, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=白细胞介素4/13单抗Dupixent销售额持续增长，但未能扭转赛诺菲因流感疫苗和糖尿病药物导致的整体销售额下降, objectType=article, longId=182339, objectId=d449182339d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d449182339d2, replyNumber=0, likeNumber=83, createdTime=2020-07-12, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d449182339d2, moduleTitle=白细胞介素4/13单抗Dupixent销售额持续增长，但未能扭转赛诺菲因流感疫苗和糖尿病药物导致的整体销售额下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d449182339d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784829, encodeId=7cbf1e84829da, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, objectType=article, longId=151494, objectId=a936151494c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a936151494c3, replyNumber=0, likeNumber=82, createdTime=2019-09-21, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a936151494c3, moduleTitle=赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a936151494c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1784834, encodeId=01311e84834d3, content=<a href='/topic/show?id=00e4633166' target=_blank style='color:#2F92EE;'>#Dupixen#</a>, objectTitle=FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉, objectType=article, longId=174393, objectId=fc561e4393b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc561e4393b5, replyNumber=0, likeNumber=92, createdTime=2020-04-10, rootId=0, userName=yanjie6253_56072842, userId=35fc2500023, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc561e4393b5, moduleTitle=FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc561e4393b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Dupixen

2020-05-29

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲/再生元的Dupixent在第二次慢性自发性荨麻疹研究中表现欠佳

2022-06-06

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

幼儿哮喘患者的福音，CHMP批准Dupixent用于患有哮喘的幼儿患者

2022-12-22

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

哮喘新药：再生元的Dupixent能够迅速改善儿童的肺功能

2022-03-18

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲、再生元的Dupixent在慢性自发性荨麻疹中取得积极成果

2021-10-27

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲的IL-4/IL-13单抗Dupixent显著减轻儿童的严重哮喘发作

2021-06-19

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

中国NMPA批准Dupixent用于特应性皮炎

2020-09-26

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲的IL-4/IL-13单抗Dupixent，在特应性皮炎儿童患者中显示出明显益处

2020-04-29

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

Dupixent在欧盟获得批准用于儿童特应性皮炎

2021-10-15

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲/再生元Dupixent获FDA突破性疗法认定

2020-11-15

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

IL-4/IL-13单抗DUPIXENT获得INESSS的积极推荐，用于治疗中度至重度特应性皮炎

2021-06-14

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

慢性皮肤病及呼吸道疾病患者的福音：FDA批准Dupixent（dupilumab）300mg预填充笔

2021-02-05

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会

2020-04-06

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

欧盟批准Dupixent治疗严重慢性鼻窦炎伴鼻息肉

2019-12-15

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

全球特应性皮炎靶向生物制剂Dupixent® 亮相进博会

2020-08-10

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲白细胞介素4/13单抗Dupixent在严重特应性皮炎儿童患者的III期试验成功

2020-07-13

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

Dupixent中国内地首针注射在博鳌超级医院完成

2019-11-10

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲：Dupixent（dupilumab）治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果 

2019-09-04

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

白细胞介素4/13单抗Dupixent销售额持续增长，但未能扭转赛诺菲因流感疫苗和糖尿病药物导致的整体销售额下降

2020-07-12

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

赛诺菲旗下Dupixent获得FDA批准用于中重度哮喘

2019-09-21

yanjie6253_56072842 (审核中...)

前往app查看评论内容

#Dupixen#

FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉

2020-04-10

科室
- - 订阅+
  - 更多科室
工具
服务